Reports Q1 revenue $11.2B, consensus $10.71B. “Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers (BMY) Squibb. “We are advancing our multi-year plan to become a more agile and efficient company, while strengthening the foundation for top-tier, long-term growth. Our strategy is clear, and our actions are accelerating the delivery of transformational medicines to patients.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Optimistic Buy Rating for Bristol-Myers Squibb Amid Low Valuation and Promising Pipeline
- Notable companies reporting before tomorrow’s open
- Bristol Myers price target lowered to $68 from $70 at Jefferies
- Bristol Myers price target lowered to $51 from $55 at Citi
- Bristol-Myers Squibb: Hold Rating Amid Clinical Challenges and Growth Uncertainty